Doctors and Nurses Told to Admit Mistakes

According to new guidelines, face-to-face explanations and apologies will need to be given to patients or close ones when things regarding their treatment and wellbeing go wrong. The guidance follows Sir Robert Francis’ call for a more open and transparent culture within healthcare in his report following the failures in patient care at Mid Staffordshire

Continue Reading

NHS: £190m set aside for Hepatitis C

The budget for HCV therapies will be increased from last year’s £40 million to £190 million says NHSE (NHS England). This will provide stop-gap access to drugs such as AbbVie’s on Viekirax and Exviera to around 3,500 patients with cirrhosis. NHSE’s Clinical Priorities Advisory Group (CPAG) is recommending that Viekirax/Exviera should be offered to all

Continue Reading

Teva $40 Billion Offer to Acquire Mylan

Following weeks of speculation, Teva yesterday made a $40-billion-bid for Mylan NV. Teva has offered $82 per Mylan share in a 50/50 cash/stock transaction valued at just over $40 billion. However, the reaction so far to the news suggests that Teva would need to improve on their bid for it to be accepted.  S&P Capital

Continue Reading

Johnson & Johnson Exceed Q1 Estimates

Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar.  The negative currency effect is expected to continue to

Continue Reading

Takeda Signs Oncology Biotech Deal

Takeda has announced that they have signed a deal with ImmunoGen for two anticancer targets. Takeda signed the agreement with ImmunoGen through its subsidiary Millennium Pharmaceuticals. The agreement, which grants Takeda exclusive rights to use ImmunoGen’s ADC technology for anticancer therapeutics, could be worth up to $230m. Specifically, the Japanese pharmaceutical company has licensed exclusive

Continue Reading

Bristol-Myers Squibb Acquires Cancer Specialist, Flexus, for $800m

Bristol-Myers Squibb have announced that they will be acquiring Flexus Biosciences in an agreement worth up to $1.25 billion. Flexus are a biotechnology company which specialises in the discovery, development, and commercialisation of small-molecule cancer immunotherapies targeting regulatory T cells. The acquisition will involve an $800 million upfront payment, giving Bristol-Myers Squibb full rights to

Continue Reading

Roche Acquires Signature Diagnostics

Roche has today announced that they have acquired Germany’s Signature Diagnostics. Signature Diagnostics were a privately-held translational oncology and genomics company, based in Potsdam, Germany. The acquisition is the fifth deal that Roche has made within the past year, aimed at building their molecular diagnosis business. Signature Diagnostics focuses on developing large blood plasma and

Continue Reading